Keyphrases
Emergency Department
100%
Drug-related Problems
26%
Delirium
19%
Emergency Patients
18%
Acute Decompensated Heart Failure
18%
ST-elevation Myocardial Infarction (STEMI)
16%
Frailty
16%
Risk Factors
15%
Anticholinergic Burden
14%
Primary PCI
14%
At Discharge
12%
Emergency Room
11%
Frail Elderly
10%
Emergency Department Revisit
10%
Activation Time
10%
Constipation
9%
Cardiac Transplantation
9%
Intestinal Inflammation
9%
COVID-19
9%
Clinical Course
9%
Clinical Characteristics
9%
Piperacillin-tazobactam
9%
Urinary Tract Infection
9%
Oral Anticoagulants
9%
Septic Patients
9%
Ictus
9%
Hospital Emergency Department
9%
Multivariate Analysis
8%
Emergency Service
8%
Comorbidity
8%
Retrospective Observational Study
7%
Escherichia Coli
7%
Direct Oral Anticoagulants
7%
Extended Infusion
7%
Adult Patients
7%
National Institutes of Health Stroke Scale (NIHSS)
7%
Emergency Department Visits
7%
Atrial Fibrillation
7%
High Risk
7%
Hospitalized Patients
7%
Probability of Target Attainment
7%
First Medical Contact
7%
Spain
6%
Multidrug-resistant Bacteria
6%
Intervention Group
6%
Secondary Prevention
6%
Elderly Patients
6%
Transplantation
6%
Anticoagulants
6%
Therapeutic Management
6%
Medicine and Dentistry
Emergency Department
69%
Apoplexy
15%
Drug Therapy
12%
Comorbidity
11%
Triage
11%
Consultation
11%
Heart Transplantation
10%
Delirium
10%
Percutaneous Coronary Intervention
9%
Decompensated Heart Failure
9%
Cerebrovascular Disease
9%
COVID-19
9%
Antithrombotic
9%
Frailty
9%
Mortality Rate
8%
Observational Study
8%
Electrocardiogram
7%
Infection
6%
Retrospective Study
6%
Nurse
6%
National Institutes of Health Stroke Scale
6%
Brain Ischemia
5%
Cerebral Hemorrhage
5%
Tocilizumab
5%
D-Dimer
5%
Direct Oral Anticoagulant
5%
Pharmaceutical Care
5%
Clinical Trial
5%
Emergency Care
5%
Digestive System Hemorrhage
5%
Risk Stratification
5%
Emergency Medicine
5%
Atrial Fibrillation
5%
Urinary Tract Infection
5%
Health System
5%
Pharmacology, Toxicology and Pharmaceutical Science
Comorbidity
16%
Retrospective Study
14%
Cerebrovascular Accident
14%
Cholinergic Receptor Blocking Agent
14%
Observational Study
10%
Pharmacokinetics
10%
Enteritis
9%
Cerebrovascular Disease
9%
Anticoagulant Agent
9%
Constipation
9%
Piperacillin Plus Tazobactam
9%
Urinary Tract Infection
9%
Frailty
9%
Somnolence
9%
Infection
8%
Escherichia coli
8%
Pharmacotherapy
8%
Inflammation
8%
Mortality Rate
7%
Disease
7%
D Dimer
5%
Tocilizumab
5%
Adrenergic Receptor Stimulating Agent
5%
Clonidine
5%
Pharmacodynamics
5%
Survival Rate
5%
Croton Oil
5%
Abdominal Pain
5%
Adverse Event
5%
